Patents by Inventor Matthew T. Basel
Matthew T. Basel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9731034Abstract: The present invention provides a diagnostic reagent or assay for assessing the activity of a protease in vivo or in vitro and methods of detecting the presence of a cancerous or precancerous cell. The assays are comprised of two particles linked via an oligopeptide linkage that comprises a consensus sequence specific for the target protease. Cleavage of the sequence by the target protease can be detected visually or using various sensors, and the diagnostic results can be correlated with cancer prognosis.Type: GrantFiled: January 26, 2015Date of Patent: August 15, 2017Assignee: Kansas State University Research FoundationInventors: Stefan H. Bossmann, Deryl L. Troyer, Matthew T. Basel
-
Patent number: 9682155Abstract: The present invention provides a diagnostic reagent or assay for assessing the activity of a protease in vivo or in vitro and methods of detecting the presence of a cancerous or precancerous cell. The assays are comprised of two particles linked via an oligopeptide linkage that comprises a consensus sequence specific for the target protease. Cleavage of the sequence by the target protease can be detected visually or using various sensors, and the diagnostic results can be correlated with cancer prognosis.Type: GrantFiled: January 26, 2015Date of Patent: June 20, 2017Assignee: Kansas State University Research FoundationInventors: Stefan H. Bossmann, Deryl L. Troyer, Matthew T. Basel
-
Patent number: 9216154Abstract: Supramolecular assemblies for delivering active agents to cancerous or precancerous tissues in a subject are provided. These supramolecular assemblies are also useful in assays for detecting and imaging of cancerous and precancerous cells. The assemblies are protease-sensitive and comprise a peptide linkage containing a protease consensus sequence. The assemblies can be selectively targeted to cancerous tissue where the protease enzymes degrade the peptide linkage thereby releasing the active agents which were physically or mechanically contained in or retained by the supramolecular assembly.Type: GrantFiled: March 13, 2013Date of Patent: December 22, 2015Assignee: Kansas State University Research FoundationInventors: Stefan H. Bossmann, Deryl L. Troyer, Matthew T. Basel, Tej B. Shrestha, Hongwang Wang
-
Publication number: 20150132230Abstract: The present invention provides a diagnostic reagent or assay for assessing the activity of a protease in vivo or in vitro and methods of detecting the presence of a cancerous or precancerous cell. The assays are comprised of two particles linked via an oligopeptide linkage that comprises a consensus sequence specific for the target protease. Cleavage of the sequence by the target protease can be detected visually or using various sensors, and the diagnostic results can be correlated with cancer prognosis.Type: ApplicationFiled: January 26, 2015Publication date: May 14, 2015Inventors: Stefan H. Bossmann, Deryl L. Troyer, Matthew T. Basel
-
Publication number: 20150132785Abstract: The present invention provides a diagnostic reagent or assay for assessing the activity of a protease in vivo or in vitro and methods of detecting the presence of a cancerous or precancerous cell. The assays are comprised of two particles linked via an oligopeptide linkage that comprises a consensus sequence specific for the target protease. Cleavage of the sequence by the target protease can be detected visually or using various sensors, and the diagnostic results can be correlated with cancer prognosis.Type: ApplicationFiled: January 26, 2015Publication date: May 14, 2015Inventors: Stefan H. Bossmann, Deryl L. Troyer, Matthew T. Basel
-
Patent number: 8969027Abstract: The present invention provides a diagnostic reagent or assay for assessing the activity of a protease in vivo or in vitro and methods of detecting the presence of a cancerous or precancerous cell. The assays are comprised of two particles linked via an oligopeptide linkage that comprises a consensus sequence specific for the target protease. Cleavage of the sequence by the target protease can be detected visually or using various sensors, and the diagnostic results can be correlated with cancer prognosis.Type: GrantFiled: March 3, 2009Date of Patent: March 3, 2015Assignee: Kansas State University Research FoundationInventors: Stefan H. Bossmann, Deryl L. Troyer, Matthew T. Basel
-
Publication number: 20130243741Abstract: A method for photodynamic therapy treatment of cancerous cells and tissue is provided. The method comprises administering tumor-trophic cells expressing a luminescent protein to a subject. A photosensitizing agent is then separately administered to the subject, followed by an optional iron chelator. On the day of treatment, a luminogenic substrate corresponding to the luminescent protein is administered to the subject. The substrate reacts with the luminescent protein in the vicinity of the cancerous tissue to produce light which activates the photosensitizing agent resulting in the selective destruction of the cancerous tissue.Type: ApplicationFiled: September 19, 2011Publication date: September 19, 2013Applicant: KANSAS STATE UNIVERSITY RESEARCH FOUNDATIONInventors: Stefan H. Bossmann, Deryl L. Troyer, Matthew T. Basel, Tej B. Shrestha, Hongwang Wang
-
Publication number: 20120157824Abstract: The present invention provides multifunctional nanoplatforms for assessing the activity of a protease in vivo or in vitro, along with methods of imaging and detecting the presence of cancerous or precancerous tissues, and the therapeutic treatment thereof, including monitoring of treatment. The diagnostic nanoplatforms comprise nanoparticles and are linked to each other or other particles via an oligopeptide linkage that comprises a consensus sequence specific for the target protease. Cleavage of the sequence by the target protease can be detected using various sensors, and the diagnostic results can be correlated with cancer prognosis. Individual unlinked nanoplatforms are also adaptable for therapeutic hyperthermia treatment of the cancerous tissue.Type: ApplicationFiled: August 31, 2010Publication date: June 21, 2012Applicants: NANOSCALE CORPORATION, KANSAS STATE UNIVERSITY RESEARCH FOUNDATIONInventors: Stefan H. Bossmann, Deryl Troyer, Matthew T. Basel, Thilani Nishanthika Samarakoon, Hongwang Wang, Viktor Chikan, Franklin Orban Kroh, Olga Barbara Koper, Brandon Ray Walker, Xiaoxuan Leaym
-
Publication number: 20110014125Abstract: The present invention provides a diagnostic reagent or assay for assessing the activity of a protease in vivo or in vitro and methods of detecting the presence of a cancerous or precancerous cell. The assays are comprised of two particles linked via an oligopeptide linkage that comprises a consensus sequence specific for the target protease. Cleavage of the sequence by the target protease can be detected visually or using various sensors, and the diagnostic results can be correlated with cancer prognosis.Type: ApplicationFiled: March 3, 2009Publication date: January 20, 2011Applicant: KANSAS STATE UNIVERSITY RESEARCH FOUNDATIONInventors: Stefan H. Bossmann, Deryl L. Troyer, Matthew T. Basel